Drug Trial Radar · NCT06388564
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
130
Actual
Start
Oct 11, 2024
Primary completion
Oct 1, 2026
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
Conditions
- Chronic Graft-versus-host-disease
Interventions
AxatilimabDrug
Axatilimab will be administered at protocol defined dose.
RuxolitinibDrug
Ruxolitinib will be administered at protocol defined dose.
CorticosteroidsDrug
Corticosteroids will be administered at protocol defined dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: 6 months
Locations
68 sites in 7 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
City of Hope Medical Center
Duarte, California
University of California-Los Angeles Medl Cntr-Oncology Center Bowyer Clinic
Los Angeles, California
Stanford Cancer Center
Stanford, California
University of Colorado Cancer Center
Aurora, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
Smilow Cancer Center-Yale
New Haven, Connecticut
Mayo Clinic Jacksonville
Jacksonville, Florida
Northwestern University
Chicago, Illinois
The University of Chicago Medicine
Chicago, Illinois
University of Maryland-Greenebaum Cancer Center
Baltimore, Maryland
Washington University
St Louis, Missouri
Fred and Pamela Buffett Cancer Center
Omaha, Nebraska
Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell Medicine
New York, New York
Mount Sinai Hospital
New York, New York
Cleveland Clinic
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania
Hillman Cancer Center
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Md Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
University of Washington
Seattle, Washington
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin
Az Sint-Jan Brugge - Oostende Av - Campus Sint-Jan
Bruges, Belgium
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, Belgium
Jessa Ziekenhuis
Hasselt, Belgium
Universitair Ziekenhuis (Uz) Leuven
Leuven, Belgium
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, Belgium
Centre Hospitalier Universitaire (Chu) de Liege
Liège, Belgium
AZ DELTA
Roeselare, Belgium
Vancouver General Hospital
Vancouver, Canada
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Princess Margaret Cancer Centre - University Health Network
Toronto, Ontario, Canada
Chu Sainte-Justine
Montreal, Quebec, Canada
Klinikum Der Johann Wolfgang Goethe University
Frankfurt am Main, Germany
Universitatklinikum Freiburg
Freiburg I. Breisgau, Germany
Universitatsklinikum Hamburg Eppendorf
Hamburg, Germany
Universitaetsklinikum Jena
Jena, Germany
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.